HERBAL SLIM CLA
- MAY HELP TO SUPPORT A MODEST IMPROVEMENT TO BODY COMPOSITION WHEN USED WITH A PROGRAM OF REDUCED INTAKE OF DIETARY CALORIES AND INCREASED PHYSICAL ACTIVITY.
- MAY HELP TO SUPPORT A MODEST REDUCTION IN FAT MASS WHEN USED WITH A PROGRAM OF REDUCED INTAKE OF DIETARY CALORIES AND INCREASED PHYSICAL ACTIVITY.
CLA IS A NATURALLY OCCURRING FATTY ACID FOUND IN MEAT AND DAIRY PRODUCTS, BUT NOT AT LEVELS HIGH ENOUGH TO RECEIVE OPTIMAL BENEFITS. HERBAL SLIM CLA CONTAINS HIGHLY CONCENTRATED NATURAL CLA DERIVED FROM SAFFLOWER OIL.
CAUTION(S) AND WARNING(S):
CONSULT A HEALTH CARE PRACTITIONER PRIOR TO USE IF YOU ARE OBESE OR HAVE CARDIOVASCULAR DISEASE (CVD) RISK FACTORS (E.G. HIGH BLOOD PRESSURE, HIGH CHOLESTEROL AND/OR TRIGLYCERIDES)
CONSULT A HEALTH CARE PRACTITIONER PRIOR TO USE IF YOU ARE PREGNANT OR BREASTFEEDING
CONSULT A HEALTH CARE PRACTITIONER PRIOR TO USE IF YOUR GOAL IS TO ACHIEVE WEIGHT LOSS.
CONTRAINDICATION(S):
DO NOT USE IF YOU HAVE CVD, DIABETES, METABOLIC SYNDROME OR INSULIN RESISTANCE.
KNOWN ADVERSE REACTION(S):
SOME PEOPLE MAY EXPERIENCE GASTROINTESTINAL UPSET.
CLA
BASU S, RISÉRUS U, TURPEINEN A, VESSBY B. 2000A. CONJUGATED LINOLEIC ACID INDUCES LIPID PEROXIDATION IN MEN WITH ABDOMINAL OBESITY. CLINICAL SCIENCE 99(6):511-516.
BASU S, SMEDMAN A, VESSBY B. 2000B. CONJUGATED LINOLEIC ACID INDUCES LIPID PEROXIDATION IN HUMANS. FEBS LETTERS 468(1):33-36.
BERVEN G, BYE A, HALS O, BLANKSON H, FAGERTUN H, THOM E, WADSTEIN J, GUDMUNDSEN O. 2000. SAFETY OF CONJUGATED LINOLEIC ACID (CLA) IN OVERWEIGHT AND OBESE HUMAN VOLUNTEERS. EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY 102(7):455-462.
BLANKSON H, STAKKESTAD JA, FAGERTUN H, THOM E, WADSTEIN J, GUDMUNDSEN O. 2000. CONJUGATED LINOLEIC ACID REDUCES BODY FAT MASS IN OVERWEIGHT AND OBESE HUMANS. THE JOURNAL OF NUTRITION 130(12):2943-2948.
FDA 2007: UNITED STATES FOOD AND DRUG ADMINISTRATION. GUIDANCE FOR INDUSTRY DEVELOPING PRODUCTS FOR WEIGHT MANAGEMENT DRAFT GUIDANCE [ONLINE]. WASHINGTON (DC): UNITED STATES DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. FOOD AND DRUG ADMINISTRATION. AVAILABLE FROM: HTTP://WWW.FDA.GOV/DOWNLOADS/DRUGS/GUIDANCECOMPLIANCEREGULATORYINFORMATION/GUIDANCES/UCM071612.PDF
GAULLIER JM, HALSE J, HOYE K, KRISTIANSEN K, FAGERTUN H, VIK H, GUDMUNDSEN O. 2004. CONJUGATED LINOLEIC ACID SUPPLEMENTATION FOR 1 Y REDUCES BODY FAT MASS IN HEALTHY OVERWEIGHT HUMANS. THE AMERICAN JOURNAL OF CLINICAL NUTRITION 79:1118-1125.
GAULLIER JM, HALSE J, HOYE K, KRISTIANSEN K, FAGERTUN H, VIK H, GUDMUNDSEN O. 2005. SUPPLEMENTATION WITH CONJUGATED LINOLEIC ACID FOR 24 MONTHS IS WELL TOLERATED BY AND REDUCES BODY FAT MASS IN HEALTHY, OVERWEIGHT HUMANS. THE JOURNAL OF NUTRITION 135(4):778-784.
GAULLIER JM, HALSE J, HØIVIK HO, HØYE K, SYVERTSEN C, NURMINIEMI M, HASSFELD C, EINERHAND A, O'SHEA M, GUDMUNDSEN O. 2007. SIX MONTHS SUPPLEMENTATION WITH CONJUGATED LINOLEIC ACID INDUCES REGIONAL-SPECIFIC FAT MASS DECREASES IN OVERWEIGHT AND OBESE. BRITISH JOURNAL OF NUTRITION 97(3):550-560.
This page is not intended to be a comprehensive review of the medicinal ingredient.
| NPN |
PRODUCT CODE |
POTENCY |
CAPSULE |
| 80043192 |
AAB0069 |
1,000MG CLA |
60 SOFTGELS |
.png)
